ストックスクリーナーアプリを入手
7.08
4.46%
0.35
アフターアワーズ：
7.08
前日終値:
$6.73
開ける：
$6.525
24時間の取引高:
114.13K
Relative Volume:
1.45
時価総額：
$112.44M
収益：
-
当期純損益:
$-12.36M
株価収益率:
-5.659
EPS:
-1.2511
ネットキャッシュフロー:
$-11.39M
1週間 パフォーマンス:
+9.67%
1か月 パフォーマンス:
+21.00%
6か月 パフォーマンス:
+16.78%
1年 パフォーマンス:
-26.39%
1日の値動き範囲:
$6.31
$7.19
1週間の範囲:
$5.805
$7.19
52週間の値動き範囲:
$4.75
$10.69
Coya Therapeutics Inc Stock (COYA) Company Profile
名前
Coya Therapeutics Inc
セクター
電話
650.739.3939
住所
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
COYA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
7.08 | 112.44M | 0 | -12.36M | -11.39M | -1.2511 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-04 | 開始されました | D. Boral Capital | Buy |
Coya Therapeutics Inc (COYA) 最新ニュース
Can GLP-1 Agonists Transform Alzheimer's Treatment? Coya Therapeutics Experts Weigh In - StockTitan
Coya reports promising Alzheimer's treatment study results - MSN
Long Term Trading Analysis for (COYA) - Stock Traders Daily
Robust Growth in AI in Clinical Trials Market (2025-2032): - openPR
Newbridge Financial Services Group Inc. Makes New Investment in Coya Therapeutics, Inc. (NASDAQ:COYA) - MarketBeat
Coya Therapeutics (NASDAQ:COYA) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from Chardan Capital - MarketBeat
(COYA) Trading Advice - Stock Traders Daily
BTIG maintains Coya Therapeutics stock buy rating, $15 target - MSN
Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD (NASDAQ:COYA) - Seeking Alpha
Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch - Seeking Alpha
Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's disease - Marketscreener.com
Coya Therapeutics Inc (COYA) Shares Rise Despite Market Challenges - The News Heater
Coya reports promising Alzheimer’s treatment study results By Investing.com - Investing.com Nigeria
Coya: Low-Dose IL-2 in AD patients resulted in reduced proinflammatory markers - TipRanks
Coya Therapeutics, Inc. Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development - Marketscreener.com
Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing - AOL
Why Is Coya Therapeutics Stock Trading Higher Today?Coya Therapeutics (NASDAQ:COYA) - Benzinga
Coya Therapeutics Inc Reports Significant Improvement In Inflammatory Markers In Alzheimer's Patients - Marketscreener.com
Coya reports promising Alzheimer's treatment study results By Investing.com - Investing.com UK
Breakthrough: Alzheimer's Drug Delivers 4.93-Point Memory Score Gain in Clinical Trial - StockTitan
Coya Therapeutics CEO to Showcase Novel T Cell Platform at Major Healthcare Conference - StockTitan
(COYA) Long Term Investment Analysis - Stock Traders Daily
An ALS treatment wave is approaching, and this biotech CEO is ready to surf - PharmaVoice
Coya Therapeutics advances COYA 303 for inflammatory diseases By Investing.com - Investing.com Australia
Coya Therapeutics (NASDAQ:COYA) Given “Buy” Rating at D. Boral Capital - Defense World
Coya Therapeutics' (COYA) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
EXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory Diseases - AOL
Coya Therapeutics advances COYA 303 for inflammatory diseases - Investing.com India
Coya Therapeutics Unveils COYA 303: Novel GLP-1 Combination Therapy for Inflammatory Diseases - StockTitan
Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Up 10.2% in December - MarketBeat
Revolutionizing Success in the AI in Clinical Trials Market: - openPR
Geode Capital Management LLC Has $918,000 Stake in Coya Therapeutics, Inc. (NASDAQ:COYA) - Defense World
How to Take Advantage of moves in (COYA) - Stock Traders Daily
Coya Therapeutics (NASDAQ:COYA) Receives "Buy" Rating from D. Boral Capital - MarketBeat
Coya Therapeutics enrolls five in FTD study, eyes Phase 2 trial - Investing.com
Objective long/short (COYA) Report - Stock Traders Daily
Regulatory T-cells (Tregs) Therapies Market Key Players - openPR
Factors Influencing Global Regulatory T Cell Tregs Therapies - openPR
Exosome Therapeutics Market Applications in Neurological - openPR
Boral Capital initiates coverage on Coya Therapeutics with Buy rating By Investing.com - Investing.com Canada
Coya Therapeutics (NASDAQ:COYA) Now Covered by D. Boral Capital - MarketBeat
D. Boral Capital Initiates Coverage of Coya Therapeutics (COYA) with Buy Recommendation - MSN
INNOVATIONMAP EMAILS ARE AWESOME - InnovationMap
Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference - StockTitan
Alzheimer’s Disease Market Size to Reach US$ 6.3 Billion by 2034, Impelled by Advancements in Early Detection - IMARC Group
Coya Therapeutics files to sell 1.38M shares of common stock for holders - MSN
Coya Therapeutics sets sights on neurodegenerative trials in 2025 - Investing.com India
Coya Therapeutics Advances $700M ALS Program, Sets Key 2025 Clinical Milestones | COYA Stock News - StockTitan
Trend Tracker for (COYA) - Stock Traders Daily
Insider Buying: CFO David Snyder Acquires Shares of Coya Therape - GuruFocus.com
Coya Therapeutics Inc (COYA) 財務データ
収益
当期純利益
現金流量
EPS
Coya Therapeutics Inc (COYA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Swaminathan Arun | Chief Executive Officer |
Nov 13 '24 |
Buy |
7.36 |
5,000 |
36,797 |
10,000 |
| Grossman Fred | Chief Medical Officer |
Nov 11 '24 |
Buy |
7.37 |
2,710 |
19,973 |
2,710 |
| Swaminathan Arun | Chief Executive Officer |
Nov 11 '24 |
Buy |
7.34 |
5,000 |
36,689 |
5,000 |
2.95%
0.31%
大文字化:
|
ボリューム (24 時間):